3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
90
Triple Negative Breast Neoplasms
18
Stomach Neoplasms
14
Inflammatory Breast Neoplasms
12
Esophageal Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
5
Testicular Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma
3
Adenocarcinoma Of Esophagus
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Carcinoma, Hepatocellular
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms, Male
2
pCR Rate
1
Women With Primary Breast Cancer
1
Upper Tract Urothelial Carcinoma
1
Unilateral HER2 Positive Breast Cancer
1
Thymoma
1
Testicular Germ Cell Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Rare Tumour
1
Prostatic Neoplasms
1
Primary Breast Cancer
1
Interventions
Carboplatin
5
Trastuzumab
4
Paclitaxel
4
Cyclophosphamide
3
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
pertuzumab
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Vorinostat
1
Thiotepa
1
Taxes
1
Radiotherapy
1
Pharmaceutical Preparations
1
Melphalan
1
Lapatinib
1
Imatinib Mesylate
1
Epirubicin
1
Drugs, Investigational
1
Doxorubicin
1
Docetaxel
1
Denosumab
1
Cryosurgery
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Ductal, Breast
×
Epirubicin
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled